Gbs Inc Down 11.43% To $0.56 After Earnings

Thursday, September 1, 2022 - Gbs Inc (GBS) reported downside earnings and upside revenues.

Gbs Inc's earnings came in at an EPS loss of $0.14 per share. The firm's loss per share narrowed by 26% since reporting a loss of $0.19 per share a year ago. Remember, earnings reported were on an adjusted basis, so they may not be comparable to prior reports and/or analyst estimates.

Gbs Inc reported a revenue of $66.9 thousand in Q4 2022. The firm managed negative 89% growth year-over-year due to Gbs Inc reporting quarterly revenue of $587.9 thousand in its year-ago quarter. Gbs Inc achieved a higher earnings growth rate than revenue, signaling that the business has improved its profit margin.

The stock is down 11.43% to $0.56 after the report.

Gbs Inc's revenues declined at a faster pace than earnings.

Trading in the five days leading up to the report earned Gbs Inc a Bearish Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 26.

GBS Inc is a United States-based company engaged in manufacturing of Saliva Glucose Biosensor (SGB). SGB uses saliva to measure glucose non-invasively. The Saliva Glucose Test consists of the SGB which is a single-use disposable saliva biosensor and the software app that interfaces the SGB with its digital information system.